UT-MD Anderson Cancer Center: ASH - Targeted Oral Therapy Reduced Disease Burden and Improved Symptoms for Patients With Rare Blood Disorder
December 11, 2023
December 11, 2023
HOUSTON, Texas, Dec. 11 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
Bezuclastinib was safe and rapidly lowered markers of disease burden for patients with nonadvanced systemic mastocytosis in Phase II trial
* * *
ABSTRACT: 77
The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blo . . .
* * *
Bezuclastinib was safe and rapidly lowered markers of disease burden for patients with nonadvanced systemic mastocytosis in Phase II trial
* * *
ABSTRACT: 77
The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blo . . .